Bronchopulmonary Dysplasia Treatment Market 2034: EMA, PDMA, FDA Approvals, Prevalence, Medication, Clinical Trials, Therapies, and Companies by DelveInsight

Bronchopulmonary Dysplasia Companies are Medipost Co, Oak Hill Bio/Takeda, Chiesi Farmaceutici, PNEUMOSTEM, Airway Therapeutics, Emmes Company, Medipost Co Ltd., Chiesi Pharmaceuticals, Mallinckrodt, Abbott, Shire, and others.
(Albany, USA) DelveInsight's "Bronchopulmonary Dysplasia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Bronchopulmonary Dysplasia, historical and forecasted epidemiology as well as the Bronchopulmonary Dysplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Bronchopulmonary Dysplasia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Bronchopulmonary Dysplasia market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Achondroplasia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Bronchopulmonary Dysplasia market.

To Know in detail about the Bronchopulmonary Dysplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bronchopulmonary Dysplasia Market Forecast [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key facts of the Bronchopulmonary Dysplasia Market Report:

* The Bronchopulmonary Dysplasia market size was valued approximately USD 0.028 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
* In October 2024, Airway Therapeutics, Inc., a biopharmaceutical company focused on developing a new class of biologics to disrupt the cycle of injury and inflammation in respiratory and inflammatory diseases, announced it will initiate a multinational Phase 3 clinical trial in December 2024. The trial will evaluate zelpultide alfa (rhSP-D) for the prevention of bronchopulmonary dysplasia (BPD) and reduction of associated lung damage in preterm infants.
* In 2023, the total number of incident cases of Bronchopulmonary Dysplasia (BPD) in the 7MM was approximately 17,091. It is projected that these cases will rise by the year 2032.
* In 2023, the United States reported the highest number of incident cases of Bronchopulmonary Dysplasia (BPD) among the 7MM, totaling around 13,276 cases.
* In the EU4 countries and the UK, Germany reported the highest incidence of Bronchopulmonary Dysplasia (BPD) with 930 cases in 2023, followed closely by France with 920 cases. In contrast, Spain had the lowest incidence of BPD in the same year.
* According to DelveInsight's analysts, assessments indicate that in the United States, there were about 5,225 cases of Bronchopulmonary Dysplasia (BPD) among preterm infants weighing less than or equal to 750 g, followed by 5,043 cases in the 751-1000 g group, 2,300 cases in the 1001-1250 g group, and 709 cases in the greater than or equal to 1250 g group in 2023.
* Currently, the Bronchopulmonary Dysplasia pipeline is sparse, featuring primarily OHB607 (mecasermin rinfabate), an intravenous infusion under development by Oak Hill. Additional developments include PNEUMOSTEM (Human Umbilical Cord Blood Derived Mesenchymal Stem Cells) by Medipost, and AT-100 by Airway Therapeutics, among others.
* Key Bronchopulmonary Dysplasia Companies: Medipost Co, Oak Hill Bio/Takeda, Chiesi Farmaceutici, PNEUMOSTEM, Airway Therapeutics, Emmes Company, Medipost Co Ltd., Chiesi Pharmaceuticals, Mallinckrodt, Abbott, Shire, and others
* Key Bronchopulmonary Dysplasia Therapies: PNEUMOSTEM Registered , OHB-607, CHF5633, Medipost, AT-100, Furosemide Cohort, PNEUMOSTEM Registered , Curosurf, Infasurf, palivizumab, rhIGF-I/rhIGFBP-3, and others
* The Bronchopulmonary Dysplasia epidemiology based on gender analyzed that the severityspecific data reveal the highest number of preterm infants have mild Bronchopulmonary Dysplasia
* The Bronchopulmonary Dysplasia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bronchopulmonary Dysplasia pipeline products will significantly revolutionize the Bronchopulmonary Dysplasia market dynamics.

Bronchopulmonary Dysplasia Overview

Bronchopulmonary Dysplasia (BPD) is a chronic lung disease that primarily affects premature infants who require prolonged oxygen therapy or mechanical ventilation due to underdeveloped lungs. It is characterized by inflammation and scarring in the lungs, leading to breathing difficulties and long-term respiratory issues.

BPD typically occurs in preterm babies born before 32 weeks of gestation, especially those with very low birth weight (



This release was published on openPR.